A Randomized, Double-blind, Placebo-controlled, Phase 2a Crossover Study to Evaluate the Effect of the TRPV4 Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2017
At a glance
- Drugs GSK 2798745 (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 09 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Jun 2017 Planned End Date changed from 20 Jul 2017 to 11 Aug 2017.
- 15 Jun 2017 Planned primary completion date changed from 20 Jul 2017 to 11 Aug 2017.